Prostate Cancer

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.

Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

Reviews a case of a patient with high PSA but no other symptoms.

Explains the importance of respect and collaboration between care providers.

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

Focuses on patients being active participants in their treatment choices.

Highlights the advantages of various providers working together for patient care.

Panel discusses how collaboration between specialties improves patient outcomes.

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Marijo Bilusic, MD, PhD, discusses key considerations and unanswered questions regarding the use of PARP inhibitors in patients with prostate cancer.

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

Howard I. Scher, MD, took a passion for improving cancer care and patient outcomes in prostate cancer and turned it into an extraordinary and explosive field of clinical research.

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Brief background on prostate cancer and overview of the program.

Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.

Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.